ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Archives for 2023

Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment

Erin Jungmeyer
on: December 19, 2023In: Evolving Standards of Care, Meeting News
Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment

According to research presented during the North America Conference on Lung Cancer, moving away from pack-years of smoking history to duration of smoking history would increase the number of Black patients who qualify for screening to a rate comparable to that of white patients. Read more


Mesothelioma Patients Experienced Higher Levels of Toxicity on CheckMate743 Regimen Than Reported in Clinical Trials

Erin Jungmeyer
on: December 19, 2023In: Evolving Standards of Care
Mesothelioma Patients Experienced Higher Levels of Toxicity on CheckMate743 Regimen Than Reported in Clinical Trials

Dr. Ned McNamee said the RIOMeso study is the first detailed report of real-world outcomes in Australian patients undergoing ipi + nivo treatment for pleural meso. Read more

IASLC Announces Partnerships to Spur Oncogene-Driven Lung Cancer Research, Address Global Challenges in Conquering Thoracic Cancers

Erin Jungmeyer
on: December 19, 2023In: Global Initiatives, Society News
IASLC Announces Partnerships to Spur Oncogene-Driven Lung Cancer Research, Address Global Challenges in Conquering Thoracic Cancers

The initiatives include a $2.5 million, 4-year research grant and projects to improve lung cancer biomarker testing uptake around the world. Read more

Patient Advocacy in 2023: A Look Back at Advocacy Efforts, Patient Concerns

Angus Pratt, MBA
on: December 05, 2023In: Patient Advocacy
Patient Advocacy in 2023: A Look Back at Advocacy Efforts, Patient Concerns

Patient research advocate Angus Pratt reflects on the past year of advocacy coverage in ILCN and how the movement has evolved in recent years. Read more

Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

Erin Jungmeyer
on: December 05, 2023In: Diagnostic Oncology, Evolving Standards of Care
Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

Researchers evaluating the clinical significance of IASLC-proposed criteria found the recommendations better align with clinicopathologic risk factors and improve prognostication. Read more

IASLC Calls For Documentation of Tobacco Use in Cancer Clinical Trials

Erin Jungmeyer
on: December 05, 2023In: Society News, Tobacco Control & Smoking Cessation
IASLC Calls For Documentation of Tobacco Use in Cancer Clinical Trials

The association recommends collecting data on tobacco use status to advance knowledge on the impacts of tobacco smoke in the context of cancer clinical trials. Read more

Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2

Ivy Elkins, MBA
on: November 21, 2023In: Evolving Standards of Care, Patient Advocacy
Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2

In light of recent data from the study of osimertinib with or without chemotherapy, patient advocate Ivy Elkins said the results may sway some to add chemo to their first-line treatment plan. However, for others, the impact on quality of life will not be worth it. Read more

Transporting Real-World Evidence Between Countries—Ready to Beam Aboard?

Jamie Feng, MD
+more
on: November 21, 2023In: Evolving Standards of Care
Transporting Real-World Evidence Between Countries—Ready to Beam Aboard?

When novel agents demonstrate high rates of durable treatment response but comparative outcome data with standard treatments are lacking, it is important to have methods to translate those treatments to different settings. Read more

Data Support IMRT as Standard of Care for Locally Advanced NSCLC

Fred Gebhart
on: November 21, 2023In: Meeting News, Radiation Oncology, WCLC News
Data Support IMRT as Standard of Care for Locally Advanced NSCLC

During the 2023 World Conference on Lung Cancer, Dr. Stephen Chun said long-term data show intensity-modulated radiation therapy offers an overall survival benefit and reduced toxicity compared to 3D conformal radiation therapy. Read more

Media Training Improves Advocacy Reach, Increases Lung Cancer Awareness

Fred Gebhart
on: November 21, 2023In: Meeting News, Patient Advocacy, WCLC News
Media Training Improves Advocacy Reach, Increases Lung Cancer Awareness

LungCAN Co-Chair Dusty Donaldson says training program helped just two advocates reach more than 630 million people in 32 states and five countries. Read more

1234›»

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy